[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Biermasz NR, Smit JW, Pereira AM, Frölich M, Romijn JA, Roelfsema F: Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary; 2007;10(3):237-49
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients.
  • During medical treatment basal GH secretion remained (slightly) elevated and secretory regularity was decreased in 24 h blood sampling studies.
  • We did not observe development of tachyphylaxis towards the drug or radiological evidence of (growing) metastases.
  • We propose life-long suppressive therapy with somatostatin analogs in cases with persisting elevated serum GHRH concentrations after removal of the primary tumor.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Human Growth Hormone / secretion. Lung Neoplasms / secretion. Pancreatic Neoplasms / secretion. Paraneoplastic Endocrine Syndromes / metabolism. Parathyroid Neoplasms / secretion
  • [MeSH-minor] Adult. Entropy. Female. Hormones / blood. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Octreotide. Pituitary Gland / pathology. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7686-90 [2823271.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jul;75(1):281-4 [1619020.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Endocrinology. 1989 Nov;125(5):2710-8 [2507296.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Mar;32(3):315-21 [2111746.001]
  • [Cites] Endocrinology. 1990 Nov;127(5):2149-56 [2226307.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):569-76 [1908480.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Endocr Rev. 1992 Aug;13(3):476-98 [1425484.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Am J Physiol. 1994 Apr;266(4 Pt 2):H1643-56 [8184944.001]
  • [Cites] J Clin Invest. 1994 Sep;94(3):1277-88 [8083369.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3746-53 [8855833.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Feb;82(2):634-7 [9024267.001]
  • [Cites] Neurosurgery. 1997 Mar;40(3):611-4; discussion 614-5 [9055303.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):394-400 [9150699.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):123-35 [9302383.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):688-92 [9467594.001]
  • [Cites] Eur J Endocrinol. 1998 Feb;138(2):164-9 [9506860.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14894-8 [10611309.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):700-12 [11158034.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R721-9 [11171650.001]
  • [Cites] Arch Intern Med. 2001 Apr 9;161(7):1010-1 [11295968.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2227-30 [11344231.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):3764-73 [11517152.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2001 Dec;281(6):R1975-85 [11705784.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2002 Jun;110(4):188-92 [12058343.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] Eur J Endocrinol. 2002 Sep;147(3):381-6 [12213676.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):536-9 [12527856.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E25-30 [14506078.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] Br Med J (Clin Res Ed). 1984 Aug 25;289(6443):453-5 [6432140.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2097-108 [6435852.001]
  • [Cites] J Clin Invest. 1985 May;75(5):1584-90 [2860126.001]
  • [Cites] Presse Med. 1985 Dec 7;14(42):2129-34 [2868453.001]
  • [Cites] Am J Physiol. 1986 Apr;250(4 Pt 1):E486-93 [3008572.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Sep;113(1):23-8 [2876570.001]
  • [Cites] Am J Surg Pathol. 1987 Oct;11(10):810-9 [2889383.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Feb;48(2):243-50 [9579239.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):582-9 [10022420.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):192-200 [10216513.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1761-2 [10323416.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3241-7 [10487694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4776-80 [16968791.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):445-50 [2898285.001]
  • (PMID = 17541749.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  • [Other-IDs] NLM/ PMC2045692
  •  go-up   go-down


2. Sasaki M, Funayama H, Asano T, Kasono K, Namai K, Tamemoto H, Ueno S, Ota M, Kawakami M, Shinoda S, Ishikawa SE: Full-blown Cushing's disease after an episode of pituitary apoplexy. Endocr J; 2003 Oct;50(5):501-6
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-blown Cushing's disease after an episode of pituitary apoplexy.
  • The present study reports a rare case of full-blown Cushing's disease several years after an episode of pituitary apoplexy.
  • Ten years ago she had an episode of pituitary apoplexy.
  • Diabetes mellitus was diagnosed at age 56, and thereafter she had been controlled her plasma glucose with diet therapy and oral hypoglycemic agents.
  • Dexamethasone suppression test showed that a large dose of 8 mg dexamethasone, but not a small dose of 2 mg, suppressed the pituitary-adrenocortical axis.
  • Brain T(1)-weighted magnetic resonance imaging depicted a low signal of pituitary tumor, which was not enhanced by gadolinium.
  • The pituitary tumor was removed by transsphenoidal adenomectomy, and immunohistochemistry revealed an ACTH-producing adenoma.
  • The evidence suggested the possibility that the two pituitary tumors with dormant period of several years were a recurrence of ACTH-producing tumors in the present patient.
  • [MeSH-major] Cushing Syndrome / etiology. Pituitary Apoplexy / complications
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Adenoma / secretion. Adenoma / surgery. Administration, Oral. Adrenocorticotropic Hormone / secretion. Diabetes Complications. Diabetes Mellitus / diet therapy. Diabetes Mellitus / drug therapy. Female. Humans. Hypoglycemic Agents / administration & dosage. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Obesity / complications. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14614205.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


3. Ahtiainen P, Sharp V, Rulli SB, Rivero-Müller A, Mamaeva V, Röyttä M, Huhtaniemi I: Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels. Endocr Relat Cancer; 2010 Sep;17(3):611-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced LH action in transgenic female mice expressing hCGbeta-subunit induces pituitary prolactinomas; the role of high progesterone levels.
  • The etiology of pituitary adenomas remains largely unknown, with the exception of involvement of estrogens in the formation of prolactinomas.
  • We have examined the molecular pathogenesis of prolactin-producing pituitary adenomas in transgenic female mice expressing the human choriongonadotropin (hCG) beta-subunit.
  • Curiously, despite normal estrogen levels, large prolactinomas developed in these mice, and we provide here several lines of evidence that the elevated P(4) levels are involved in the growth of these estrogen-dependent tumors.
  • The antiprogestin mifepristone inhibited tumor growth, and combined postgonadectomy estradiol/P(4) treatment was more effective than estrogen alone in inducing tumor growth.
  • Evidence for direct growth-promoting effect of P(4) was obtained from cultures of primary mouse pituitary cells and rat somatomammotroph GH3 cells.
  • The mouse tumors and cultured cells revealed stimulation of the cyclin D1/cyclin-dependent kinase 4/retinoblastoma protein/transcription factor E2F1 pathway in the growth response to P(4).
  • If extrapolated to humans, and given the importance of endogenous P(4) and synthetic progestins in female reproductive functions and their pharmacotherapy, it is relevant to revisit the potential role of these hormones in the origin and growth of prolactinomas.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):168-74 [10634382.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):113-22 [18852162.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1998 Jan;3(1):63-72 [10819505.001]
  • [Cites] J Neuroendocrinol. 2001 Mar;13(3):302-9 [11207946.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4479-85 [11564713.001]
  • [Cites] J Clin Invest. 2002 Jan;109(2):277-83 [11805140.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):4084-95 [12239120.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35819-25 [12121979.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4536-43 [12446580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1034-9 [12552124.001]
  • [Cites] Front Horm Res. 2004;32:34-62 [15281339.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(16):7260-74 [15282324.001]
  • [Cites] Science. 1966 Oct 21;154(3747):402-3 [4288164.001]
  • [Cites] Endocrinology. 1970 Mar;86(3):503-5 [5410438.001]
  • [Cites] J Endocrinol. 1973 Feb;56(2):309-14 [4703244.001]
  • [Cites] Endocrinology. 1976 Dec;99(6):1482-9 [826392.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2133-6 [7061411.001]
  • [Cites] Adv Exp Med Biol. 1981;138:151-63 [7342713.001]
  • [Cites] Arch Pathol Lab Med. 1983 Sep;107(9):488-91 [6309114.001]
  • [Cites] Cancer Res. 1985 Mar;45(3):1015-9 [2982481.001]
  • [Cites] J Endocrinol. 1989 Jun;121(3):409-17 [2547009.001]
  • [Cites] Endocrinology. 1991 Jul;129(1):270-6 [1711463.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1546-9 [8453621.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:1-5 [8396832.001]
  • [Cites] Hum Reprod. 1994 Jun;9 Suppl 1:63-8 [7962471.001]
  • [Cites] J Cell Sci Suppl. 1994;18:89-96 [7883799.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4892-8 [7585526.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20608-16 [8702807.001]
  • [Cites] J Endocrinol. 1996 Nov;151(2):175-84 [8958777.001]
  • [Cites] Endocrinology. 1998 Apr;139(4):1602-9 [9528940.001]
  • [Cites] EMBO J. 1998 Apr 1;17(7):2008-18 [9524123.001]
  • [Cites] Nat Genet. 1998 Apr;18(4):360-4 [9537419.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Endocrinology. 2005 Nov;146(11):4917-25 [16123159.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7301-9 [16007123.001]
  • [Cites] Cancer Cell. 2006 Jun;9(6):459-71 [16766265.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):71-80 [18196959.001]
  • [Cites] Horm Metab Res. 2008 Apr;40(4):245-50 [18548383.001]
  • [Cites] Eur J Endocrinol. 2008 Sep;159(3):197-202 [18567667.001]
  • [Cites] J Reprod Med. 1999 Dec;44(12 Suppl):1121-6 [10649822.001]
  • (PMID = 20453081.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / / 063552; United Kingdom / Wellcome Trust / / 082101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 4G7DS2Q64Y / Progesterone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  • [Other-IDs] NLM/ PMC2881531
  •  go-up   go-down


Advertisement
4. Otsuka F, Mizobuchi S, Ogura T, Sato K, Yokoyama M, Makino H: Long-term effects of octreotide on pituitary gigantism: its analgesic action on cluster headache. Endocr J; 2004 Oct;51(5):449-52
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term effects of octreotide on pituitary gigantism: its analgesic action on cluster headache.
  • We report the case of 19-year-old man with pituitary gigantism due to growth hormone-producing pituitary macroadenoma.
  • Octreotide administration was initiated following transsphenoidal pituitary adenomectomy.
  • Octreotide injection for 4 years efficaciously reduced the size of remnant adenoma as well as serum growth hormone levels.
  • The analgesic effect lasted 2 to 6 hours after each injection and no tachyphylaxis to octreotide appeared during 4-year treatment.
  • To characterize the headache and the pain intensity, analgesic drugs including octreotide, lidocaine, morphine and thiopental were tested using a visual analogue scale (VAS) evaluation, with the result that octreotide exhibited a prompt and complete disappearance of the headache.
  • The present case suggests that the intractable headache associated with pituitary gigantism is possibly related to the endogenous opioid system.
  • [MeSH-major] Adenoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Cluster Headache / drug therapy. Gigantism / drug therapy. Octreotide / administration & dosage. Pituitary Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Gigantism.
  • Genetic Alliance. consumer health - Cluster headache.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15516776.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antineoplastic Agents, Hormonal; 76I7G6D29C / Morphine; RWM8CCW8GP / Octreotide
  •  go-up   go-down


5. Drake WM, Berney DM, Kovacs K, Monson JP: Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant. Eur J Endocrinol; 2005 Aug;153(2):203-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomant.
  • We report our findings on markers of cell proliferation (Ki-67 labelling index and topoisomerase-alpha expression) in a somatotroph pituitary tumour before and after exposure to pegvisomant, a GH receptor antagonist developed for the treatment of acromegaly.
  • Specimens from two separate pituitary operations, separated by a period of 17 years that included 4 years of pegvisomant treatment, were stained for markers of cellular proliferation.
  • Clearly, caution must be exercised when interpreting findings from a single case, particularly one sufficiently refractory to conventional therapies to require treatment with pegvisomant.
  • However, our data reinforce the requirement for careful radiological surveillance of the pituitary in the context of a drug that does not target the tumour responsible and where serum GH cannot serve as a marker of disease activity or tumour size.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061824.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


6. Laczi F, Magony S, Julesz J: [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide]. Orv Hetil; 2002 May 12;143(19 Suppl):1062-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
  • In each case, a growth hormone-producing pituitary adenoma was responsible for the development of acromegaly (microadenomas in 3 and macroadenomas in the rest of the patients).
  • Treatment with long-acting octreotide was indicated for those patients who had not reacted satisfactorily upon previous therapeutic procedures or proved to be unsuitable for irradiation therapy and/or surgery or refused both of these therapies.
  • After a 6-month treatment, the daily mean of serum growth hormone became suppressed below 2.5 ng/ml in 58.3% of the patients, whereas the growth hormone nadir during oral glucose tolerance test was found at or below 2.5 ng/ml in an even higher proportion of patients (70%).
  • During a 2-year period, the growth hormone-suppressive effect of long-acting octreotide remained stable in all but one patient.
  • The size of the pituitary adenomas remarkably decreased in 50% of this patient cohort.
  • The medication with this preparation was well tolerated.
  • The present retrospective study yields evidence for the microcapsulated octreotide to be an effective tool in the modern therapy of acromegaly.
  • [MeSH-major] Acromegaly / drug therapy. Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Delayed-Action Preparations. Diabetes Mellitus / chemically induced. Drug Administration Schedule. Female. Glucose Intolerance / chemically induced. Hormones / therapeutic use. Human Growth Hormone / blood. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12063861.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Delayed-Action Preparations; 0 / Hormones; 12629-01-5 / Human Growth Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


7. Kobayashi T, Mori Y, Uchiyama Y, Kida Y, Fujitani S: Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure? J Neurosurg; 2005 Jan;102 Suppl:119-23
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of gamma knife surgery for growth hormone-producing pituitary adenoma: is the disease difficult to cure?
  • OBJECT: The authors conducted a study to determine the long-term results of gamma knife surgery for residual or recurrent growth hormine (GH)-producing pituitary adenomas and to compare the results with those after treatment of other pituitary adenomas.
  • The mean maximum dose was 35.3 Gy and the mean margin dose was 18.9 Gy.
  • Growth hormone normalization (GH < 1.0 ng/ml) was found in 4.8%, nearly normal (< 2.0 ng/ml) in 11.9%, significantly decreased (< 5.0 ng/ml) in 23.8%, decreased in 21.4%, unchanged in 21.4%, and increased in 16.7%.
  • CONCLUSIONS: Gamma knife surgery was effective and safe for the control of tumors; however, normalization of GH and IGF-1 secretion was difficult to achieve in cases with large tumors and low-dose radiation.
  • Gamma knife radiosurgery is thus indicated for small tumors after surgery or medication therapy when a relatively high-dose radiation is required.
  • [MeSH-major] Adenoma / secretion. Adenoma / surgery. Human Growth Hormone / secretion. Pituitary Neoplasms / secretion. Pituitary Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Outcome Assessment (Health Care). Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Prolactinoma / pathology. Prolactinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662793.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


8. Shomali ME, Katznelson L: Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary; 2002;5(2):89-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas.
  • Clinically nonfunctioning pituitary adenomas are one of the most common types of pituitary tumors.
  • Unless they present with symptoms related to local mass effect, most tumors are detected incidentally when imaging studies are performed for other reasons.
  • Although clinically nonfunctioning, most of these tumors have evidence, in vitro, of gonadotropin hormone or glycoprotein subunit production.
  • When these tumors present as macroadenomas, often with associated mass effect and hypopituitarism, primary therapy is neurosurgery.
  • The role for medical therapy will be reviewed here.
  • [MeSH-major] Adenoma / drug therapy. Adenoma / secretion. Gonadotropins / secretion. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / secretion
  • [MeSH-minor] Dopamine Agonists / therapeutic use. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Somatostatin / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3635-40 [11502789.001]
  • [Cites] J Clin Invest. 1997 Nov 1;100(9):2386-92 [9410919.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):937-41 [6200493.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):81-6 [2535852.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Oct;73(4):850-6 [1653785.001]
  • [Cites] Pituitary. 2001 Aug;4(3):173-8 [12138990.001]
  • [Cites] Med Electron Microsc. 2000;33(1):25-31 [11810454.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Aug;41(2):177-84 [7523001.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jan;66(1):96-102 [2447115.001]
  • [Cites] J Endocrinol Invest. 1985 Apr;8(2):113-5 [4031376.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):395-401 [6886753.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Sep;63(3):564-9 [2426298.001]
  • [Cites] Neurol Med Chir (Tokyo). 2000 Sep;40(9):453-6; discussion 456-7 [11021076.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Oct;31(4):411-23 [2627747.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14 (1):53-7 [11790981.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 May;22(5):679-86 [4028461.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jun;81(6):2165-70 [8964846.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jun;68(6):1128-35 [2542356.001]
  • [Cites] Q J Med. 1989 Feb;70(262):145-60 [2594955.001]
  • [Cites] Clin Endocrinol (Oxf). 1981 Aug;15(2):103-12 [6796297.001]
  • [Cites] Am J Med. 1986 Sep;81(3):457-62 [3092668.001]
  • [Cites] Aust N Z J Med. 1987 Apr;17(2):249-51 [3039955.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Jun;62(6):1173-9 [3009521.001]
  • [Cites] J Endocrinol Invest. 1993 Jul-Aug;16(7):541-3 [8227984.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S31-6 [11762349.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Mar;42(3):544-50 [767353.001]
  • [Cites] Trends Endocrinol Metab. 2001 Mar;12(2):58-64 [11167123.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Apr;70(4):859-64 [1690748.001]
  • [Cites] J Neurosurg. 1998 Dec;89(6):933-8 [9833818.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Dec;25(6):697-702 [3652470.001]
  • [Cites] Eur J Endocrinol. 2000 Sep;143(3):313-5 [11022170.001]
  • [Cites] Trends Endocrinol Metab. 1992 Mar;3(2):41-5 [18407076.001]
  • [Cites] Endocrinology. 1998 Jul;139(7):3342-51 [9645710.001]
  • [Cites] Endocrinol Metab Clin North Am. 2000 Mar;29(1):205-21 [10732272.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Feb;22(2):147-53 [2985300.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Jul;43(1):97-106 [820707.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):336-40 [1973174.001]
  • [Cites] J Endocrinol Invest. 2001 Jun;24(6):430-7 [11434667.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Oct;61(4):666-71 [2863281.001]
  • [Cites] Am J Pathol. 1980 Mar;98(3):617-38 [6244736.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Nov;25(5):561-72 [3621623.001]
  • [Cites] Ann Intern Med. 1994 May 15;120(10):817-20 [8154641.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Sep;41(3):551-5 [1099115.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(4):417-31 [2426859.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 May;30(5):475-84 [2605786.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):73-80 [2535851.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Nov;47(5):589-98 [9425399.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jan;54(1):23-30 [11167922.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Jun;64(6):1187-93 [2437140.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Jun;32(6):681-8 [2116944.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Nov;82(11):3625-32 [9360517.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Jun;74(6):1343-51 [1375599.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):536-42 [3102541.001]
  • [Cites] Acta Neuropathol. 1983;62(1-2):1-14 [6318500.001]
  • [Cites] Eur J Endocrinol. 1994 Apr;130(4):339-45 [8162161.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1318-25 [1358910.001]
  • [Cites] J Clin Invest. 1987 Nov;80(5):1472-8 [2824561.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):166-70; discussion 170-1 [9442519.001]
  • [Cites] Neurosurgery. 1997 Oct;41(4):786-95; discussion 796-7 [9316039.001]
  • [Cites] Q J Med. 1989 May;71(265):417-27 [2602541.001]
  • [Cites] Clin Endocrinol (Oxf). 1980 Sep;13(3):215-22 [6163576.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):905-11 [9269826.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Nov;41(5):661-6 [7828356.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Sep;61(3):580-4 [2410444.001]
  • [Cites] Arch Intern Med. 1995 Jan 23;155(2):181-3 [7811127.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Sep;61(3):525-8 [2991325.001]
  • [Cites] J Endocrinol Invest. 2000 Jul-Aug;23 (7):463-6 [11005271.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1352-5 [8077332.001]
  • [Cites] N Engl J Med. 1981 May 21;304(21):1254-9 [6163984.001]
  • [Cites] J Clin Endocrinol Metab. 1976 Sep;43(3):650-7 [956349.001]
  • [Cites] J Endocrinol. 1998 May;157(2):177-86 [9659280.001]
  • [Cites] Ann Intern Med. 1982 Mar;96(3):281-6 [7059088.001]
  • [Cites] J Endocrinol Invest. 1994 Feb;17(2):91-8 [8006338.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Sep;71(3):718-24 [2394776.001]
  • [Cites] Acta Endocrinol (Copenh). 1988 Aug;118(4):533-7 [2840793.001]
  • [Cites] Endocrinol Metab Clin North Am. 1997 Dec;26(4):725-40 [9429857.001]
  • [Cites] JAMA. 1990 May 23-30;263(20):2772-6 [2332920.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Nov;75(5):1310-7 [1430093.001]
  • [Cites] Digestion. 2000;62 Suppl 1:27-32 [10940684.001]
  • [Cites] Endocr Pathol. 1995 Summer;6(2):115-124 [12114647.001]
  • [Cites] Horm Res. 1993;40(4):149-55 [7507880.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Dec;73(6):1248-55 [1720125.001]
  • [Cites] Eur J Endocrinol. 1999 Oct;141(4):396-408 [10526255.001]
  • [Cites] Clin Endocrinol (Oxf). 1984 Aug;21(2):123-9 [6205794.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Mar;48(3):331-7 [9578824.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Jul;65(1):65-73 [3034958.001]
  • [Cites] J Neurosurg. 1987 Feb;66(2):244-50 [3543255.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):1048-55 [12170092.001]
  • [Cites] Mol Endocrinol. 1996 Dec;10(12):1688-96 [8961277.001]
  • [Cites] Surg Neurol. 1988 Jun;29(6):443-7 [3375972.001]
  • [Cites] J Clin Endocrinol Metab. 1993 May;76(5):1363-8 [8496331.001]
  • [Cites] Eur J Endocrinol. 2001 Jun;144(6):569-75 [11375790.001]
  • [Cites] J Neurosurg. 1979 Jul;51(1):42-6 [448417.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):369-76 [9150695.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):1-7 [6689702.001]
  • (PMID = 12675506.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR01066; United States / NIA NIH HHS / AG / R29 AG15882
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Gonadotropins; 33515-09-2 / Gonadotropin-Releasing Hormone; 51110-01-1 / Somatostatin
  • [Number-of-references] 100
  •  go-up   go-down


9. Schopohl J, Gutt B: [Therapy of pituitary diseases. What can be achieved with medication and hormones?]. MMW Fortschr Med; 2001 Nov 1;143(44):34-9
MedlinePlus Health Information. consumer health - Pituitary Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of pituitary diseases. What can be achieved with medication and hormones?].
  • [Transliterated title] Therapie hypophysärer Erkrankungen. Was Sie mit Medikamenten und Hormonen erreichen können.
  • Pharmacotherapy is available only for pituitary adenomas producing growth hormone and prolactin (acromegaly, hyperprolactinemia).
  • While dopamine agonists and somatostatin analogues are usually administered to acromegaly patients only after unsuccessful surgery, dopamine agonists are the treatment of choice in patients with prolactinomas.
  • Replacement treatment in patients with insufficiency of the anterior lobe of the hypophysis is oriented to the extent of the deficits.
  • Theoretically, replacement treatment can be applied for any functional loss.
  • In adults, replacement of growth hormone is also indicated to decrease cardiovascular risk.
  • [MeSH-major] Pituitary Diseases / drug therapy
  • [MeSH-minor] Acromegaly / drug therapy. Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Dopamine Agonists / administration & dosage. Dopamine Agonists / therapeutic use. Female. Follow-Up Studies. Hormones / administration & dosage. Hormones / therapeutic use. Human Growth Hormone / administration & dosage. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / therapeutic use. Humans. Hypogonadism / drug therapy. Hypopituitarism / drug therapy. Magnetic Resonance Imaging. Male. Middle Aged. Octreotide / administration & dosage. Octreotide / therapeutic use. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / drug therapy. Pregnancy. Prolactinoma / diagnosis. Prolactinoma / drug therapy. Somatostatin / administration & dosage. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11732393.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Dopamine Agonists; 0 / Hormones; 0 / Peptides, Cyclic; 0 / pegvisomant; 118992-92-0 / lanreotide; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; RWM8CCW8GP / Octreotide
  • [Number-of-references] 0
  •  go-up   go-down


10. Wiesner TD, Trantakis C, Meixensberger J, Koch CA, Zimmer C, Paschke R: [Structure of an interdisciplinary pituitary outpatient care unit at the University Hospital of Leipzig and results for treatment of prolactin and growth hormone secreting pituitary tumors]. Med Klin (Munich); 2005 Apr 15;100(4):173-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Structure of an interdisciplinary pituitary outpatient care unit at the University Hospital of Leipzig and results for treatment of prolactin and growth hormone secreting pituitary tumors].
  • [Transliterated title] Arbeitsweise einer interdisziplinären neurochirurgisch-endokrinologischen Sprechstunde für Hypophysentumoren am Universitätsklinikum Leipzig und Ergebnisse der Behandlung von hormonaktiven Hypophysenadenomen.
  • BACKGROUND: Treatment of patients with pituitary adenomas is complex and involves several medical specialties.
  • At the Medical Center of the University of Leipzig, Germany, an interdisciplinary pituitary outpatient care unit has been established for 6 years.
  • METHODS: The interdisciplinary collaboration and the outcome of patients with growth hormone-(GH-) and prolactin-secreting pituitary adenomas are described.
  • Moreover, therapeutic strategies for patients with hormonally active pituitary adenomas are presented and discussed.
  • RESULTS: In patients suffering from GH-producing adenomas, a remission could be achieved in 80% (microadenomas) and 40% (macroadenomas) of the cases, respectively.
  • Furthermore, prolactinomas decreased in size during treatment in at least 75% of all cases depending on the initial size of the lesion which is also comparable to data from other groups.
  • CONCLUSION: Taken together, an interdisciplinary approach improves outcome and quality of care of patients with hormonally active pituitary adenomas.
  • [MeSH-major] Adenoma / therapy. Pituitary Neoplasms / therapy. Prolactinoma / therapy
  • [MeSH-minor] Acromegaly / drug therapy. Acromegaly / surgery. Acromegaly / therapy. Adult. Age Factors. Combined Modality Therapy. Dopamine Agonists / therapeutic use. Female. Follow-Up Studies. Germany. Growth Hormone / blood. Growth Hormone / secretion. Hospital Units. Humans. Interdisciplinary Communication. Male. Middle Aged. Outpatients. Patient Care Team. Prolactin / blood. Prolactin / secretion. Sex Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15834525.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


11. Nasr C, Mason A, Mayberg M, Staugaitis SM, Asa SL: Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma. J Clin Endocrinol Metab; 2006 Dec;91(12):4776-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acromegaly and somatotroph hyperplasia with adenomatous transformation due to pituitary metastasis of a growth hormone-releasing hormone-secreting pulmonary endocrine carcinoma.
  • CONTEXT: GHRH excess from extracranial endocrine tumors is known to cause somatotroph hyperplasia and acromegaly.
  • Hypothalamic gangliocytomas producing GHRH are also known to be associated with pituitary adenomas causing acromegaly.
  • OBJECTIVES: The objective of this study was to describe a case of acromegaly due to a pulmonary GHRH-secreting endocrine carcinoma with metastasis to the pituitary gland and to look at the peculiar histological features of this case.
  • After delivery, she underwent radiation and chemotherapy for pulmonary and skeletal metastases.
  • Her disease was clinically stable for 7 yr until she developed bitemporal hemianopia.
  • Histological examination confirmed metastatic endocrine carcinoma to the pituitary, and immunohistochemistry localized GHRH to the tumor cells.
  • The adjacent pituitary exhibited somatotroph hyperplasia with abundant reactivity for GH and alpha-subunit.
  • CONCLUSION: This is the first report of a GHRH-producing endocrine tumor metastasizing to the pituitary and causing local hyperstimulation with somatotroph hyperplasia and adenomatous transformation.
  • [MeSH-major] Acromegaly / complications. Acromegaly / etiology. Adenoma / etiology. Carcinoma / complications. Growth Hormone-Releasing Hormone / secretion. Lung Neoplasms / complications. Paraneoplastic Endocrine Syndromes / complications. Pituitary Neoplasms / secondary. Somatotrophs / pathology

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16968791.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hormones, Ectopic; 0 / Indium Radioisotopes; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


12. Kovacs K, Horvath E: Effects of medical therapy on pituitary tumors. Ultrastruct Pathol; 2005 May-Aug;29(3-4):163-7
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of medical therapy on pituitary tumors.
  • Previously surgery and irradiation were the only available procedures to treat patients with pituitary tumors.
  • During the last few decades, novel drugs such as dopamine agonists and long-acting somatostatin analogs were developed and, an alternative medical therapy emerged.
  • This paper summarizes the effect of medical therapy on the morphologic features of pituitary tumors and illustrates the ultrastructural alterations on electron micrographs.
  • Currently drugs can be used in the management of pituitary tumors secreting GH, PRL, and/or TSH in excess.
  • No medical therapy is available so far for ACTH-, FSH-, LH-, or alpha-subunit-secreting tumors as well as non-hormone-secreting pituitary tumors.
  • Dopamine agonists are effective in the management of PRL-secreting tumors; they cause marked reversible tumor shrinkage in the substantial majority of patients.
  • Long-acting somatostatin analogs are useful in the management of GH- and TSH-secreting pituitary tumors; they lead to mild to moderate tumor shrinkage in approximately 50% of cases.
  • In patients treated with these drugs reduction of elevated blood hormone levels and amelioration of clinical symptoms ensue.
  • Blood hormone levels increase and the clinical symptoms reappear after discontinuation of treatment.
  • Recently GH receptor blockers (pegvisomant) were introduced in the treatment of GH-producing pituitary adenomas.
  • To the authors' knowledge the effect of these drugs on the morphology of pituitary tumors has not been revealed so far.
  • [MeSH-major] Dopamine Agonists / therapeutic use. Human Growth Hormone / analogs & derivatives. Octreotide / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Humans. Microscopy, Electron, Transmission. Prolactin / secretion. Thyrotropin / secretion. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16036872.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; RWM8CCW8GP / Octreotide
  •  go-up   go-down


13. Mezosi E, Nemes O: [Treatment of pituitary adenomas]. Orv Hetil; 2009 Sep 27;150(39):1803-10
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of pituitary adenomas].
  • According to epidemiological studies, the prevalence of pituitary adenomas is 16.5% and the majority of them are "incidentalomas".
  • The symptoms of pituitary disorders are often non-specific; disturbances of pituitary function, compression symptoms, hypophysis apoplexy or accidental findings may help the diagnosis.
  • The hormonal evaluation of pituitary adenomas is different from the algorithm used in the disorders of peripheral endocrine organs.
  • The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease.
  • In case of tumors with good therapeutic response, medical therapy can be withdrawn after 3-5 years; hyperprolactinemia will not recur in 2/3 of these patients.
  • Neurosurgery is the primary therapy of GH-, ACTH-, TSH-producing and inactive adenomas.
  • Acromegalic patients with unresectable tumors have a great benefit from somatostatin analog treatment.
  • The growth hormone receptor antagonist pegvisomant is the newest modality for the treatment of acromegaly.
  • The medical therapy of Cushing's disease is still based on the inhibition of steroid production.
  • The rare TSH-producing tumor can respond to both dopamine agonist and somatostatin analog therapy.
  • The application of conventional radiotherapy has decreased; radiotherapy is mainly used in the treatment of invasive, incurable or malignant tumors.
  • Further studies are needed to elucidate the exact role of radiosurgery and fractionated stereotaxic irradiation in the treatment of pituitary tumors.
  • [MeSH-major] Adenoma / therapy. Pituitary Hormones / blood. Pituitary Neoplasms / therapy
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / therapy. Acromegaly / drug therapy. Acromegaly / etiology. Adrenocorticotropic Hormone / blood. Aminoquinolines / therapeutic use. Bromocriptine / therapeutic use. Cushing Syndrome / drug therapy. Cushing Syndrome / etiology. Dopamine Agonists / therapeutic use. Female. Growth Hormone-Secreting Pituitary Adenoma / therapy. Human Growth Hormone / analogs & derivatives. Human Growth Hormone / blood. Human Growth Hormone / therapeutic use. Humans. Hypophysectomy. Incidental Findings. Male. Pregnancy. Pregnancy Complications, Neoplastic / therapy. Prolactinoma / therapy. Radiosurgery. Receptors, Somatotropin / antagonists & inhibitors. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyrotropin / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19758960.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Dopamine Agonists; 0 / Pituitary Hormones; 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 3A64E3G5ZO / Bromocriptine; 51110-01-1 / Somatostatin; 80Q9QWN15M / quinagolide; 9002-60-2 / Adrenocorticotropic Hormone; 9002-71-5 / Thyrotropin; 98H1T17066 / pasireotide
  • [Number-of-references] 28
  •  go-up   go-down


14. Ragel BT, Couldwell WT: Pituitary carcinoma: a review of the literature. Neurosurg Focus; 2004 Apr 15;16(4):E7
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary carcinoma: a review of the literature.
  • Pituitary carcinomas, defined as distant metastases of a pituitary neoplasm, are rare; fewer than 140 reports exist in the English literature.
  • The initial presenting pituitary tumor is usually a secreting, invasive macroadenoma, with adrenocorticotropic hormone (ACTH)--and prolactin (PRL)--secreting tumors being the most common.
  • The latency period between the diagnosis of a pituitary tumor and the diagnosis of a pituitary carcinoma is 9.5 years for ACTH-producing lesions and 4.7 years for PRL-secreting tumors.
  • Treatment options include additional surgery, radiotherapy, and chemotherapy, all of which are associated with poor results.
  • Future studies will focus on identifying those invasive pituitary tumors most likely to metastasize and treating them aggressively before they progress to pituitary carcinomas.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adrenocorticotropic Hormone / secretion. Biomarkers, Tumor / analysis. Gene Expression Regulation, Neoplastic. Genes, p53. Genes, ras / genetics. Humans. Pituitary Gland / pathology. Pituitary Gland / ultrastructure. Point Mutation. Prolactin / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurg Focus. 2005 Sep 15;19(3):E11; author reply E11 [16196164.001]
  • (PMID = 15191336.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin
  • [Number-of-references] 122
  •  go-up   go-down


15. Vance ML: Medical treatment of functional pituitary tumors. Neurosurg Clin N Am; 2003 Jan;14(1):81-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical treatment of functional pituitary tumors.
  • Medical therapy with a dopamine agonist is the most effective for treatment of a prolactin-producing adenoma and is considered as primary treatment.
  • Surgery and pituitary radiation are reserved for patients who either do not tolerate or do not respond to a dopamine agonist drug.
  • A somatostatin analogue is effective medical therapy for patients with acromegaly, and this is usually administered if there is persistent GH hypersecretion after surgical resection.
  • Medical treatment for patients with Cushing's disease is directed at the adrenal glands to reduce cortisol hypersecretion.
  • Unfortunately, there is no effective medical therapy to reduce pituitary corticotropin production.
  • Medical therapy for a gonadotrope adenoma with a dopamine agonist or somatostatin analogue has limited utility but is employed in patients who are unable to undergo surgery and may delay or prevent additional tumor growth.
  • Many patients with a pituitary adenoma can be successfully treated with one treatment, either a dopamine agonist for a prolactinoma or surgery for other types of tumors.
  • A substantial number of patients require multimodality therapy, however, including medical therapy, surgery, and pituitary radiation.
  • Because the biologic behavior of pituitary adenomas varies considerably, a patient with a pituitary adenoma requires lifelong regular monitoring for hormone hypersecretion, tumor recurrence, and development of new pituitary hormone deficiency.
  • [MeSH-major] Adenoma / drug therapy. Pituitary Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12690980.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 53
  •  go-up   go-down


16. Lee EJ, Jameson JL: Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther; 2002 Mar 1;13(4):533-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy.
  • Diphtheria toxin has been suggested for the treatment of malignant cancer.
  • In this paper, we describe a strategy for targeting the expression of the diphtheria toxin gene to growth hormone (GH)-producing pituitary tumor cells using adenoviral vectors.
  • We generated adenoviral vectors in which a stuffer DNA fragment, flanked by two loxP sequences, was placed between the GH or cytomegalovirus (CMV) promoters and the diphtheria toxin gene (GH-loxP-DT, and CMV-loxP-DT) or the beta-Gal gene (GH-loxP-Gal, and CMV-loxP-Gal).
  • Co-infection of GH-loxP-DT with either CMV-Cre or GH-Cre induced cytotoxicity that was limited to GH4 cells.
  • Intratumoral co-injection of adenoviruses carrying diphtheria toxin (GH-loxP-DT, and CMV-loxP-DT) and Cre recombinase (GH-Cre, and CMV-Cre) caused rapid regression of the transplanted GH4 tumors.
  • These results indicate that Cre-mediated activation of a loxP-repressed form of the DT gene provides a useful strategy for targeted suicide gene therapy.
  • This approach may be useful for GH-secreting adenomas and should be applicable to other neoplastic disorders.
  • [MeSH-major] Diphtheria Toxin / genetics. Integrases / genetics. Pituitary Neoplasms / genetics. Viral Proteins / genetics
  • [MeSH-minor] Adenoviridae. Animals. Cell Death / genetics. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Genetic Therapy. Genetic Vectors. Growth Hormone / biosynthesis. Growth Hormone / genetics. Mice. Mice, Nude. Mice, Transgenic. Promoter Regions, Genetic. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11874631.001).
  • [ISSN] 1043-0342
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Viral Proteins; 9002-72-6 / Growth Hormone; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


17. Zangeneh F, Young WF Jr, Lloyd RV, Chiang M, Kurczynski E, Zangeneh F: Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma. Endocr Pract; 2003 Sep-Oct;9(5):394-9
MedlinePlus Health Information. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome due to ectopic production of corticotropin-releasing hormone in an infant with ganglioneuroblastoma.
  • OBJECTIVE: To report the first recognized case of Cushing's syndrome due to a corticotropin-releasing hormone (CRH)-secreting ganglioneuroblastoma, which was found in an 18-month-old boy with hypertensive encephalopathy.
  • The serum adrenocorticotropic hormone (ACTH) concentration was 7 pg/mL (normal, 10 to 60), and the CRH level was 439 pg/mL (normal, 24 to 40).
  • Despite discordant dynamic endocrine testing and negative somatostatin receptor scintigraphy, computed tomography showed a right 3.6- by 3.0-cm extra-adrenal retroperitoneal mass with central calcification extending 7 cm cephalocaudally.
  • The patient underwent exploratory laparotomy, followed by chemotherapy.
  • Because most CRH-producing tumors also secrete ACTH, the ectopic production may represent a paracrine phenomenon in addition to an endocrine phenomenon.
  • The ectopic CRH may also indirectly provoke pituitary ACTH secretion.
  • This dual mechanism may explain the resistance of the tumor to feedback inhibition and a CRH-stimulation response indistinguishable from that observed in pituitary-dependent Cushing's syndrome.
  • [MeSH-major] Corticotropin-Releasing Hormone / metabolism. Cushing Syndrome / etiology. Ganglioneuroblastoma / complications. Retroperitoneal Neoplasms / complications
  • [MeSH-minor] Humans. Immunohistochemistry. Infant. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14583423.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


18. Tanaka H, Kobayashi A, Bando M, Hosono T, Tsujita A, Yamasawa H, Ohno S, Hironaka M, Sugiyama Y: [Case of small cell lung cancer complicated with diabetes insipidus and Cushing syndrome due to ectopic adrenocorticotropic hormone secretion]. Nihon Kokyuki Gakkai Zasshi; 2007 Oct;45(10):793-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of small cell lung cancer complicated with diabetes insipidus and Cushing syndrome due to ectopic adrenocorticotropic hormone secretion].
  • Small-cell lung cancer (metastases in the pituitary, subcutaneous tissue, and lungs) was diagnosed by transbronchial lung biopsy and subcutaneous nodule biopsy of the abdomen.
  • Chemotherapy was done with CDDP and VP-16, which resulted in reduction of the tumor and improvement in endocrinological findings.
  • Nevertheless, chemotherapy could not be continued because of infected bullae.
  • We concluded that this case was Cushing syndrome caused by ectopic adrenocorticotropic hormone-producing small cell lung cancer, and that it presented with diabetes insipidus because of pituitary metastasis.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Carcinoma, Small Cell / complications. Cushing Syndrome / etiology. Diabetes Insipidus, Neurogenic / etiology. Lung Neoplasms / complications
  • [MeSH-minor] Fatal Outcome. Female. Humans. Middle Aged. Pituitary Neoplasms / secondary


19. Schoof E, Dörr HG, Kiess W, Lüdecke DK, Freitag E, Zindel V, Rascher W, Dötsch J: Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy. Horm Res; 2004;61(4):184-9
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Five-year follow-up of a 13-year-old boy with a pituitary adenoma causing gigantism--effect of octreotide therapy.
  • BACKGROUND/AIM: In children, there is little experience with octreotide therapy for pituitary tumors, especially growth hormone (GH) producing adenomas.
  • We report on a 13-year-old boy with gigantism due to a GH-producing pituitary adenoma caused by a Gsalpha mutation on the basis of McCune-Albright syndrome.
  • METHODS: At the age of 6.5 years a GH- and prolactin-producing pituitary adenoma was diagnosed.
  • RESULTS: During therapy with octreotide, the growth rate dropped to normal values; however, rose again after 2 years of treatment.
  • After 5 years of octreotide therapy, GH (6.9 microg/l), IGF-I (620 microg/l), IGF-binding protein 3 (5.4 mg/l), and prolactin (17.0 ng/ml) levels were still elevated.
  • A magnetic resonance imaging scan showed an unchanged residual 4-mm rim of adenoma at the pituitary site.
  • Side effects from octreotide therapy were not reported by the patient or his family.
  • The therapy was changed to the long-acting release octreotide analog octreotide-LAR.
  • After 1 year of treatment with octreotide-LAR, the GH level was 1.0 microg/l, and the prospective final height dropped by 10 cm.
  • CONCLUSIONS: This case demonstrates that combined surgical and medical treatment can influence the prognosis of childhood gigantism; however, the prognosis of this rare condition remains uncertain.
  • [MeSH-major] Adenoma / complications. Adenoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Gigantism / etiology. Octreotide / therapeutic use. Pituitary Neoplasms / complications. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. GTP-Binding Protein alpha Subunits, Gs / genetics. Human Growth Hormone / secretion. Humans. Magnetic Resonance Imaging. Male. Neoplasm, Residual / drug therapy

  • Genetic Alliance. consumer health - Gigantism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 S. Karger AG, Basel
  • (PMID = 14739526.001).
  • [ISSN] 0301-0163
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 12629-01-5 / Human Growth Hormone; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs; RWM8CCW8GP / Octreotide
  •  go-up   go-down


20. Nakagawa H, Yamamoto K: [A case of small cell lung cancer complicated by Cushing syndrome]. Nihon Kokyuki Gakkai Zasshi; 2008 Mar;46(3):210-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Marked increases in ACTH levels were observed, but no abnormality was found in the pituitary MRI findings, and therefore ACTH-producing small cell lung cancer was suspected.
  • Chemotherapy was administered in addition to appropriate treatment for Cushing's syndrome.
  • The tumor temporarily began to decrease in size, but hypercortisolemia remained, and thus adrenal hormone synthesis-inhibiting therapy was concurrently administered.
  • Therefore, from an early stage, it is believed that adrenal cortical hormone synthesis-inhibiting therapy should be performed concurrently with chemotherapy, if hypercortisolemia cannot be controlled by radiation and chemotherapy alone.
  • [MeSH-major] Carcinoma, Small Cell / complications. Cushing Syndrome / complications. Lung Neoplasms / complications

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409568.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Miyoshi T, Otsuka F, Takeda M, Inagaki K, Suzuki J, Ogura T, Date I, Hashimoto K, Makino H: Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. J Endocrinol Invest; 2004 Dec;27(11):1055-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma.
  • The present case involves a 47-yr-old woman with Cushing's disease due to pituitary macroadenoma.
  • Cranial magnetic resonance imaging (MRI) revealed a 3 cm pituitary tumor occupying the sellar region and right cavernous sinus with diffuse enhancement by gadolinium.
  • The pituitary mass was removed by transsphenoidal surgery, and was pathologically identified as compatible to ACTH-producing pituitary adenoma by immunohistochemistry.
  • In addition, cranial MRI exhibited shrinkage of the remnant pituitary mass after a 6-month treatment with cabergoline.
  • This case demonstrates the efficacy of cabergoline to treat Cushing's disease caused by pituitary macroadenoma secreting aberrant ACTH molecules.
  • [MeSH-major] Adenoma / complications. Dopamine Agonists / therapeutic use. Ergolines / therapeutic use. Pituitary ACTH Hypersecretion / drug therapy. Pituitary ACTH Hypersecretion / etiology. Pituitary Neoplasms / complications
  • [MeSH-minor] Adrenocorticotropic Hormone / secretion. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Receptors, Dopamine D2 / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):812-8 [12821114.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):1988-93 [12727942.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):904-9 [7915824.001]
  • [Cites] Mol Endocrinol. 1998 Aug;12 (8):1133-9 [9717839.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):724-63 [11739329.001]
  • [Cites] J Endocrinol Invest. 1999 Dec;22(11):860-5 [10710275.001]
  • [Cites] Ann Intern Med. 1988 Sep 15;109(6):487-93 [2843068.001]
  • [Cites] Eur J Endocrinol. 1998 Feb;138(2):153-9 [9506858.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1368-75 [9543168.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):374-8 [9467544.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):51-7 [11174837.001]
  • [Cites] Ann Intern Med. 1998 Sep 15;129(6):472-83 [9735086.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1619-23 [9589666.001]
  • [Cites] J Endocrinol Invest. 2002 Feb;25(2):172-5 [11929090.001]
  • [Cites] Horm Res. 1999;52(1):39-44 [10640899.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jul;84(7):2518-22 [10404830.001]
  • (PMID = 15754738.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Ergolines; 0 / Receptors, Dopamine D2; 9002-60-2 / Adrenocorticotropic Hormone; LL60K9J05T / cabergoline
  •  go-up   go-down


22. Chatfield J, Zhang L, Ramey J, Bowsher T, Loskutoff N, O'Neill K: Resolution of a hyperprolactinemia in a western lowland gorilla (Gorilla gorilla gorilla). J Zoo Wildl Med; 2006 Dec;37(4):565-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prolactin-secreting pituitary adenomas are one of the most common causes of infertility in women.
  • Prolactin plays an important role in lactation and is involved in producing some of the normal mammalian breeding and maternal behaviors.
  • Elevated serum prolactin concentrations can adversely affect the reproductive cycle in females by inhibiting the normal lutenizing hormone surge that stimulates ovulation.
  • An MRI confirmed a pituitary mass and treatment was initiated with cabergoline.
  • Following 8 mo of treatment, mass size decreased and serum prolactin was within normal limits.
  • The gorilla began to engage in normal breeding behavior, and within 6 mo of completing treatment, was pregnant.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ape Diseases / drug therapy. Ergolines / therapeutic use. Gorilla gorilla. Pituitary Neoplasms / veterinary. Prolactinoma / veterinary
  • [MeSH-minor] Animals. Female. Hyperprolactinemia / etiology. Hyperprolactinemia / veterinary. Reproduction / physiology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315448.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ergolines; LL60K9J05T / cabergoline
  •  go-up   go-down


23. Histrelin Hydrogel Implant--Valera: Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424. Drugs R D; 2005;6(1):53-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Valera Pharmaceuticals, formerly Hydro Med Sciences, is developing a once-yearly Histrelin Hydrogel Implant [Histrelin implant, LHRH-Hydrogel implant, RL 0903, SPD 424, Vantas], a subcutaneous (s.c.) reservoir device capable of long-term delivery of histrelin at constant release rates for the treatment of prostate cancer.
  • Histrelin is a luteinising hormone-releasing hormone agonist (LHRH).
  • A different formulation of the LHRH implant is currently in development for the treatment of central precocious puberty (CPP).
  • Shire Pharmaceuticals had an option to market and distribute the histrelin implant outside the US, but in a realigned agreement announced in January 2002, Shire stated that HydroMed (now Valera) would be responsible for concluding the phase III studies, filing for regulatory approval and producing the implant, while also gaining marketing rights in the US.
  • In July 2004, Paladin announced it had filed for regulatory approval with Health Canada for the treatment of prostate cancer.
  • Valera Pharmaceuticals believes the product may have advantages over standard prostate cancer treatments including reduced costly surgical procedures, lower dosing, increased patient compliance and peace-of-mind, as well as potentially less cost to the patient.
  • The phase III studies were completed in the second half of 2003.CPP arises from the increased release by the pituitary gland hormone gonadotropins and is characterised by an early onset of sexual development in pre-adolescents.
  • Currently, the treatment of CPP involves injections of synthetic gonadotropic hormone-releasing factor agonists such as Supprelin (histrelin acetate) and TAP Pharmaceutical's Lupron Depot-Red (leuprolide acetate) every 28 days, a potentially painful procedure.
  • This treatment inhibits pituitary release of gonadotropins.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Prostatic Neoplasms / drug therapy. Puberty, Precocious / drug therapy
  • [MeSH-minor] Drug Implants. Female. Humans. Hydrogels. Injections, Subcutaneous. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. HISTRELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801868.001).
  • [ISSN] 1174-5886
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Implants; 0 / Hydrogels; 33515-09-2 / Gonadotropin-Releasing Hormone; H50H3S3W74 / histrelin
  • [Number-of-references] 4
  •  go-up   go-down


24. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G: Hypothalamic hormones and cancer. Front Neuroendocrinol; 2001 Oct;22(4):248-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of peptide analogs for the therapy of various cancers is reviewed.
  • Inhibition of the pituitary-gonadal axis forms the basis for oncological applications of luteinizing hormone-releasing hormone (LH-RH) agonists and antagonists, but direct effects on tumors may also play a role.
  • Analogs of somatostatin are likewise used for treatment of various tumors.
  • Radiolabeled somatostatin analogs have been successfully applied for the localization of tumors expressing somatostatin receptors.
  • Studies on the role of tumoral LH-RH, growth hormone-releasing hormone (GH-RH), and bombesin/GRP and their receptors in the proliferation of various tumors are summarized, but the complete elucidation of all the mechanisms involved will require much additional work.
  • Human tumors producing hypothalamic hormones are also discussed.
  • Treatment of many cancers remains a major challenge, but new therapeutic modalities are being developed based on antagonists of GH-RH and bombesin, which inhibit growth factors or their receptors.
  • These new classes of peptide analogs should lead to a more effective treatment for various cancers.
  • [MeSH-major] Hypothalamic Hormones / physiology. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bombesin / antagonists & inhibitors. Bombesin / physiology. Breast Neoplasms / drug therapy. Female. Gastrin-Releasing Peptide / antagonists & inhibitors. Gastrin-Releasing Peptide / physiology. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / antagonists & inhibitors. Gonadotropin-Releasing Hormone / physiology. Growth Hormone-Releasing Hormone / physiology. Humans. Male. Ovarian Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / physiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11587553.001).
  • [ISSN] 0091-3022
  • [Journal-full-title] Frontiers in neuroendocrinology
  • [ISO-abbreviation] Front Neuroendocrinol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-40003; United States / NCI NIH HHS / CA / CA-40004; United States / NCI NIH HHS / CA / CA-40077
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypothalamic Hormones; 33515-09-2 / Gonadotropin-Releasing Hormone; 51110-01-1 / Somatostatin; 80043-53-4 / Gastrin-Releasing Peptide; 9034-39-3 / Growth Hormone-Releasing Hormone; PX9AZU7QPK / Bombesin
  • [Number-of-references] 160
  •  go-up   go-down


25. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: HCG induced hyperthyreosis in germ cell cancer. Anticancer Res; 2000 Nov-Dec;20(6D):5135-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human germ cell tumors have the unique capacity for totipotential differentiation.
  • AFP (the product of normal yolk sac) and HCG (produced by trophoblastic tissues) are frequently produced by germ cell tumors.
  • The a-subunit of the glycoprotein HCG is identical to that of several pituitary glycoprotein hormones (e.g.
  • However, the role of TSH within this hormone superfamily is still not yet established.
  • An ultrasound examination of the thyroid gland showed no abnormalities and no iodine exposure had occurred during the last months.
  • The patient was then entered in our phase-II-study for relapsing germ cell carcinomas using a high-dose chemotherapy regime (paclitaxel 175 mg/m2, ifosfamide 9.000 mg/m2, carboplatin 900 mg/m2, etoposide 900 mg/m2) with subsequent retransfusion of collected stem cells.
  • In this case report we have demonstrated a clear positive correlation between HCG levels and thyroidal hormones in a patient with germ cell tumor suggesting a direct stimulation of hormone producing thyroidal cells by HCG, however, this was not associated with clinical symptoms of hyperthyreosis.
  • [MeSH-major] Chorionic Gonadotropin / adverse effects. Hyperthyroidism / chemically induced. Neoplasms, Germ Cell and Embryonal / physiopathology
  • [MeSH-minor] Adult. Humans. Male. Thyroid Gland / drug effects

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11326684.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin
  •  go-up   go-down


26. Imai A, Tamaya T: GnRH receptor and apoptotic signaling. Vitam Horm; 2000;59:1-33
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition to its hypophysiotropic action, gonadotropin-releasing hormone (GnRH) can modify activity in extrapituitary organs and peripheral tumors.
  • GnRH analogs are the preferred treatment for advanced and even metastatic or recurring carcinomas in vivo and in vitro.
  • Hormone-responsive tumors undergo apoptosis with the appropriate stimulus; GnRH-induced tumor growth arrest may result from stimulated apoptotic cell death.
  • The sensitivity of tumors and normal tissue to GnRH is strongly associated with the possession of receptors for GnRH as well as other hormonal control.
  • GnRH receptors in tumors differ from those in pituitary gonadotrophs in some aspects, in particular with regard to the transmembrane signaling cascade.
  • The intramembranous phenomena that occur independently of the contribution of other organelles upon tumoral GnRH receptor engagement include (i) activation of phosphotyrosine phosphatase and loss of phosphotyrosine from the endogenous membrane protein and (ii) phosphoinositide and perhaps sphingomyelin cleavage producing lipid-originated second messengers.
  • GnRH has also been demonstrated to increase Fas ligand expression within plasma membrane, which is known to promote apoptotic cell death through attack on Fas-positive cells within tumors.
  • The Fas-Fas ligand complex might, at least in part, account for the antiproliferative action of the hormone.
  • An understanding of the relationship between the extracellular (hormonal) stimuli that leads to cell death and the intracellular events regulating growth arrest on GnRH action may fundamentally help clarify the therapeutic approach to all hormone-dependent carcinomas that respond to stimuli that lead to apoptosis.
  • [MeSH-major] Apoptosis / physiology. Fertility Agents, Female / therapeutic use. Gonadotropin-Releasing Hormone / physiology. Neoplasms, Hormone-Dependent / drug therapy. Receptors, LHRH / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714235.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fertility Agents, Female; 0 / Phosphatidylinositols; 0 / Receptors, LHRH; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  • [Number-of-references] 184
  •  go-up   go-down


27. Alves C, Alves AC: Primary hypothyroidism in a child simulating a prolactin-secreting adenoma. Childs Nerv Syst; 2008 Dec;24(12):1505-8
Hazardous Substances Data Bank. LEVOTHYROXINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hypothyroidism in a child simulating a prolactin-secreting adenoma.
  • OBJECTS: To report a case of primary hypothyroidism associated to hyperprolactinemia mimicking a prolactin secreting adenoma.
  • Diagnostic evaluation demonstrated free thyroxine (F-T4): 0.22 ng/dL (0.75-1.80) and thyroid-stimulating hormone (TSH): 135 UI/mL (0.3-5.0).
  • Pituitary magnetic resonance imaging (MRI) showed an intrasellar and suprasellar mass measuring 1.9 x 1.7 x 1.7 cm, impinging on the optic chiasm.
  • Due to the possibility of a pseudoprolactinoma caused by hyperplasia of the TSH and prolactin-producing cells, she was treated for the primary hypothyroidism with levothyroxine.
  • A new pituitary MRI, 8 months later, demonstrated a complete resolution of the pituitary mass confirming the initial suspicion of thyrotroph hyperplasia.
  • [MeSH-major] Adenoma / diagnosis. Hypothyroidism / diagnosis. Pituitary Neoplasms / diagnosis. Prolactin / secretion
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Hyperprolactinemia / blood. Hyperprolactinemia / drug therapy. Magnetic Resonance Imaging. Thyroxine / administration & dosage. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Reprod Med. 2002 Nov;20(4):365-74 [12536359.001]
  • [Cites] CMAJ. 2003 Sep 16;169(6):575-81 [12975226.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):181-5 [16009175.001]
  • [Cites] Horm Res. 2005;63(2):61-4 [15668525.001]
  • [Cites] Eur Radiol. 2000;10(3):516-8 [10757007.001]
  • [Cites] Intern Med. 2001 Aug;40(8):751-5 [11518117.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Mar;82(3):808-11 [9062487.001]
  • [Cites] Treat Endocrinol. 2003;2(1):23-32 [15871552.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):276-9 [7829625.001]
  • [Cites] Pediatr Neurosurg. 1998 Apr;28(4):195-7 [9732247.001]
  • [Cites] Endocrinol Metab Clin North Am. 2001 Sep;30(3):585-610 [11571932.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2004 Jun;48(3):423-6 [15640908.001]
  • [Cites] Australas Radiol. 1999 Feb;43(1):121-3 [10901888.001]
  • [Cites] Pediatr Neurol. 1994 Mar;10(2):166-8 [8024669.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001 Nov-Dec;14(9):1665-9 [11795659.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] Indian Pediatr. 2001 Apr;38(4):432-3 [11313523.001]
  • [Cites] JAMA. 1989 Dec 8;262(22):3175-7 [2810675.001]
  • [Cites] Br J Neurosurg. 1990;4(2):107-12 [2357279.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2005 Jun;49(3):468-72 [16544004.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Feb;58(2):185-91 [12580934.001]
  • (PMID = 18690463.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-62-4 / Prolactin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down






Advertisement